Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.

Puyuan XingShouzheng WangQiang WangDi MaXuezhi HaoMengzhao WangYan WangLi ShanTao XinLi LiangHongge LiangYang DuZhaohui ZhangJun-Ling Li

Published in: Targeted oncology (2020)

ALK-rearranged advanced NSCLC patients with baseline brain metastasis can still achieve OS benefits from crizotinib treatment. However, patients with intracranial progression may not obtain a long-term survival benefit from continuation of CBPD.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
resting state
white matter
functional connectivity
small cell lung cancer
cerebral ischemia
tyrosine kinase
double blind